TRPA1 and migraine disorder: In recent years, our group has developed a family of lipoic acid-based TRPA1 antagonists named ADM, which are able to revert not only oxaliplatin-induced neuropathic pain [17,18,19] but also inflammatory trigeminal allodynia [20], which is particularly relevant in the treatment of orofacial pain [21] and migraine pain [22].